



Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

November 6, 2024

PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day.

A webcast of the presentation will be available [here](#) beginning at 1:30 pm ET on Tuesday, November 12, 2024 and will be posted on the Investors section of the Company's [website](#).

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK[®] is the Company's first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit <http://www.krystalbio.com>, and follow @KrystalBiotech on [LinkedIn](#) and [X](#) (formerly Twitter).

CONTACT

Investors and Media:

Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com



Source: Krystal Biotech, Inc.